{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036403","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.068819+00:00","generated_at":"2026-06-04T07:32:12.498791+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iridex reports Q4 2023 revenue of $12.5M, net loss of $3.0M; full-year revenue down 9%","bullets":["Q4 2023 total revenue $12.5M vs $15.2M YoY; net loss $3.0M ($0.18 per share) vs $1.1M loss in Q4 2022.","Full-year 2023 revenue $51.9M (down 9% from $57.0M); net loss $9.6M ($0.59 per share) vs $7.5M loss in 2022.","Cyclo G6 product family Q4 revenue $3.0M (down 29%); sold 12,700 probes vs 16,400 a year ago.","Strategic review ongoing; management expects to reach first asset sale agreement soon.","Cash use reduced to $1.0M in Q4; cash and equivalents $7.0M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036403","json":"https://secwatch.observer/filing/0000950170-24-036403.json","markdown":"https://secwatch.observer/filing/0000950170-24-036403.md","text":"https://secwatch.observer/filing/0000950170-24-036403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017024036403/0000950170-24-036403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017024036403/irix-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:32:12.498791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ae11ac1f96cc2998de40ef60679633841afe77a","claim":"IRIDEX CORP reported the year ended December 30, 2023 results: revenue $51.9 million.","evidence_excerpt":"Revenue for the year ended December 30, 2023 was $51.9 million compared to $57.0 million in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017024036403/0000950170-24-036403-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 30, 2023"},{"label":"Revenue","value":"$51.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ef1bca983a11b4ba834e1bd6fee28b291faae31c","claim":"IRIDEX CORP reported the fourth quarter ended December 30, 2023 results: revenue $12.5 million, net income Net loss for the fourth quarter of 2023 was $3.0 million, EPS $0.18 per share.","evidence_excerpt":"Revenue for the three months ended December 30, 2023 was $12.5 million compared to $15.2million during the same period of the prior year. Retina product revenue decreased 7% compared to the prior year period to $7.5 million. Total product revenue from the Cyclo G6 glaucoma product group was $3.0 million, a decrease of $1.2 million versus the fourth quarter of 2022. Other revenue decreased to $2.0 million in the fourth quarter of 2023 compared to the prior year period of $2.9 million, primarily driven by decreased royalties due to expiration of licensed patents and lower service revenue. Fourth quarter revenue was impacted by several factors. In the retina business, deferral of capital purchases led to lower system sales in the U.S. and internationally, international distributors destocked inventory in advance of new laser platform launches and to minimize any potential impact from transactions resulting from Iridex’s strategic review. The Company experienced isolated supply chain limit","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017024036403/0000950170-24-036403-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 30, 2023"},{"label":"Revenue","value":"$12.5 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 was $3.0 million"},{"label":"EPS","value":"$0.18 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}